Efficacy and safety of Daratumumab for the treatment of ABO-incompatible pure red cell aplasia after allogenic HSCT: report from SFGM-TC
- 9 March 2024
- journal article
- letter
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 59 (6) , 893-895
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Prevalence of Pure Red Cell Aplasia Following Major ABO-Incompatible Hematopoietic Stem Cell TransplantationFrontiers in Immunology, 2022
- Daratumumab for pure red cell aplasia post ABO incompatible allogeneic hematopoietic stem cell transplant for aplastic anemiaBlood Cells, Molecules, and Diseases, 2021
- Pure Red Cell Aplasia following ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation: Resolution with Daratumumab TreatmentActa Haematologica, 2021
- Treatment for pure red cell aplasia after major ABO‐incompatible allogeneic stem cell transplantation: a multicentre studyBritish Journal of Haematology, 2021
- Daratumumab for delayed RBC engraftment following major ABO mismatched haploidentical bone marrow transplantationTransfusion, 2021
- Successful treatment of refractory red cell aplasia after allogeneic hematopoietic cell transplantation with daratumumabEuropean Journal of Haematology, 2019
- Daratumumab for Delayed Red-Cell Engraftment after Allogeneic TransplantationNew England Journal of Medicine, 2018
- Efficacy and Long-Term Outcome of Treatment for Pure Red Cell Aplasia after Allogeneic Stem Cell Transplantation from Major ABO-Incompatible DonorsTransplantation and Cellular Therapy, 2013
- Incidence and natural history of pure red cell aplasia in major ABO‐mismatched haematopoietic cell transplantationBritish Journal of Haematology, 2013
- Persistence of recipient plasma cells and anti‐donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non‐myeloablative haematopoietic cell transplantationBritish Journal of Haematology, 2005